|
Anxiety
|
0.020 |
Biomarker
|
disease |
BEFREE |
JNK1 controls adult hippocampal neurogenesis and imposes cell-autonomous control of anxiety behaviour from the neurogenic niche.
|
27843149 |
2018 |
|
Anxiety Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
JNK1 controls adult hippocampal neurogenesis and imposes cell-autonomous control of anxiety behaviour from the neurogenic niche.
|
27843149 |
2018 |
|
Anxiety
|
0.020 |
Biomarker
|
disease |
BEFREE |
JNK1 controls adult hippocampal neurogenesis and imposes cell-autonomous control of anxiety behaviour from the neurogenic niche.
|
28194007 |
2018 |
|
Anxiety Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
JNK1 controls adult hippocampal neurogenesis and imposes cell-autonomous control of anxiety behaviour from the neurogenic niche.
|
28194007 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
JNK1 as a signaling node in VDR-BRAF induction of cell death in AML.
|
28765039 |
2018 |
|
Acute monocytic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
JNK1 as a signaling node in VDR-BRAF induction of cell death in AML.
|
28765039 |
2018 |
|
Colitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Jun N-terminal kinase inhibition decreased SP-induced miR-31-3p expression. miR-31-3p expression was increased in both TNBS- and DSS-induced colitis and human colonic biopsies from ulcerative colitis, compared with controls.
|
29253460 |
2018 |
|
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Jun N-terminal kinase inhibition decreased SP-induced miR-31-3p expression. miR-31-3p expression was increased in both TNBS- and DSS-induced colitis and human colonic biopsies from ulcerative colitis, compared with controls.
|
29253460 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
JNK1 and VDR act as tumor suppressors, and their stromal expression levels are associated with prognosis in esophageal squamous cell carcinoma.
|
29423673 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
JNK drives the transcriptional induction of mitogenic molecules, matrix metalloproteases and systemic signals that lead to tumor growth, tissue invasiveness and malignancy.
|
29451063 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
JNK drives the transcriptional induction of mitogenic molecules, matrix metalloproteases and systemic signals that lead to tumor growth, tissue invasiveness and malignancy.
|
29451063 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
JNK drives the transcriptional induction of mitogenic molecules, matrix metalloproteases and systemic signals that lead to tumor growth, tissue invasiveness and malignancy.
|
29451063 |
2018 |
|
Tumor Progression
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
JNK and Yorkie drive tumor progression by generating polyploid giant cells in Drosophila.
|
29535423 |
2018 |
|
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
JNK, a member of the mitogen activated protein kinases (MAPKs) superfamily, plays a key role in cell death in many neurological disorders, but systemic inhibition of JNK has detrimental side effects.
|
29684334 |
2018 |
|
Intraocular pressure disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
JNK activation occurred in RGCs following increased intraocular pressure in D2 mice.
|
29899326 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MAPK8 was one of the DEGs and was up-regulated in TMZ resistant glioblastoma cells.
|
30119215 |
2018 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MAPK8 was one of the DEGs and was up-regulated in TMZ resistant glioblastoma cells.
|
30119215 |
2018 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MAPK8 was one of the DEGs and was up-regulated in TMZ resistant glioblastoma cells.
|
30119215 |
2018 |
|
Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MAPK8 was one of the DEGs and was up-regulated in TMZ resistant glioblastoma cells.
|
30119215 |
2018 |
|
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Jun N-terminal kinase 1 (JNK1) pathway and Mucin 2 (MUC2) were the potential downstream proteins of miR-613/ATOH1. miR-613 is an oncogene in CC and promotes the proliferation, invasion and migration of CC cells by targeting ATOH1 likely via activating JNK1 pathway and upregulating MUC2.
|
30219232 |
2018 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Jun N-terminal kinase 1 (JNK1) pathway and Mucin 2 (MUC2) were the potential downstream proteins of miR-613/ATOH1. miR-613 is an oncogene in CC and promotes the proliferation, invasion and migration of CC cells by targeting ATOH1 likely via activating JNK1 pathway and upregulating MUC2.
|
30219232 |
2018 |
|
Epilepsy, Temporal Lobe
|
0.020 |
Biomarker
|
disease |
BEFREE |
JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy.
|
30685843 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
JNK activity has been implicated in the malignant proliferation, invasion and drug-resistance of glioma cells (GCs), but the molecular mechanisms underlying JNK activation are currently unknown.
|
30963560 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
JNK inhibitor treatment combined with the overexpression of p57KIP2 significantly decreased the levels of apoptosis and increased cell invasion and migration.
|
31059007 |
2019 |
|
Septicemia
|
0.080 |
Biomarker
|
disease |
BEFREE |
JNK pathway-associated phosphatase is of good value in predicting lower sepsis risk, and its downregulation correlates with advanced disease severity, higher level of systemic inflammation, and poor survival in sepsis patients.
|
31206807 |
2019 |